Bio News
Brazilian pharmaceutical company Biolab Pharma is partnering with Swiss company Sandoz to launch the semaglutide product Owwgi in Brazil. Owwgi is a synthetic semaglutide product that can be used for up to 42 days without refrigeration and is the first product of its kind approved domestically. Biolab will handle promotion to health care professionals and sales, while Sandoz will supply the product. The companies are targeting a fourth-quarter launch this year.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
